Chemotherapy can significantly prolong the survival of patients with breast cancer; Nevertheless, the majority of patients receiving chemotherapy such as doxorubicin may have cognitive deficits that manifest as impairments in learning, reasoning, attention, and memory. The phenomenon of chemotherapy-induced cognitive decline is termed as chemotherapy-related cognitive impairment (CRCI) or chemo-brain. Doxorubicin (DOX), a commonly used drug in adjuvant chemotherapy for patients with breast cancer, has been reported to induce chemo-brain through a variety of mechanisms including DNA damage, oxidative stress, inflammation, dysregulation of apoptosis and autophagy, changes in neurotransmitter levels, mitochondrial dysfunction, glial cell interactions, neurogenesis inhibition, and epigenetic factors. These mechanisms do not operate independently but are inter-related, coordinately contributing to the development of chemo-brain. Here we review the relationships of these mechanisms and pathways in attempt to provide mechanistic insights into the doxorubicin-induced cognitive impairment.

Keywords: doxorubicin, cognition, mechanism, oxidative stress, inflammatory response

Chemotherapy is one of the effective conventional and widely used treatments for patients with cancer. Unfortunately, up to 70% of cancer patients receiving chemotherapy may develop cognitive impairment during or after treatment, which negatively affects their life-quality (1, 2). Since 1990s, it has been known that chemotherapy has adverse effects on brain function, causing dysfunctions in learning, memory, attention, motor activity, and executive function (3, 4). Numerous studies have shown that tyrosine kinases, antimetabolites, microtubule inhibitors, and alkylating agents all can induce neurotoxicity (5–7). Doxorubicin belongs to the anthracycline class and is commonly used in the adjuvant chemotherapy regimens for breast cancer (8). Doxorubicin exerts its antitumor effects through DNA insertion and inhibition of topoisomerase II. In addition, doxorubicin causes the production of invasive systemic reactive oxygen species (ROS) (9). Notably, despite its limited passage through the blood-brain barrier (BBB), doxorubicin can still cause severe neurotoxicity in

Abbreviations: DSBs, DNA double-strand breaks; BRCA1, breast cancer type 1 susceptibility protein; ROS, reactive oxygen species; MOMP, mitochondrial outer membrane permeability; mPTP, mitochondrial permeability transition pore; PLD, phospholipase D; ChAT, choline acetyltransferase; AChE, acetylcholinesterase; 5-HT, serotonin; DA, dopamine; ERK, extracellular signal-regulated kinase; BDNF, brain-derived neurotrophic factor; NF-κB, nuclear factor-κB; TNFR, TNF-α receptor; TNFRI, TNF-α receptor 1; TNFRII, TNF-α receptor 2; NOX, NADPH oxidases; MnSOD, manganese superoxide dismutase; ApoA-1, Apolipoprotein A-I.
the brain, and several clinical studies reported that patients of all ages treated with doxorubicin exhibited impaired ability in cognitive assessments (10–13).

Both direct or indirect mechanisms contribute to the doxorubicin-induced cognitive deficits, and the inter-relation among the multiple mechanisms are complex. A better understanding of those mechanisms and pathways and their coordinative operations may help devise novel therapeutic interventions to prevent or treat chemotherapy-induced cognitive impairment.

**DIRECT NEUROTOXICITY**

It was generally believed that doxorubicin has a limited capacity to penetrate the blood-brain barrier and thus the brain is protected from its damage. However, several studies have shown that doxorubicin has potential antitumor effects on brain cancer (14). Clinical as well as animal studies have shown that doxorubicin was detected in the brain after peripheral administration of the drug (15, 16). Recently, it was reported that doxorubicin could cross the blood-brain barrier through vascular-associated apical projections of neural stem cells (which are about 30 nm in diameter), can establish direct membrane-membrane contacts with the endothelial cells in specific regions of the irregular endothelial basement membrane, and have abundant vesicular activity (17). The possible direct mechanisms of doxorubicin induced chemobrain are illustrated in Table 1 and Figure 1.

**DNA Damage**

An important mechanism by which doxorubicin kills cancer cells is its ability to effectively cross-link with DNA, resulting in disruption of the cell cycle and subsequent death of cancer cells (23, 42). However, doxorubicin can also damage normal and non-cancerous cells (43).

Manchon et al. proved that doxorubicin accumulated in the nucleus of neurons, leading to DNA double-strand breaks (DSBs) and DNA cross-linking. Furthermore, breast cancer type 1 susceptibility protein (BRCA1), which is responsible for DNA repair, was downregulated in primary cortical neurons after doxorubicin treatment (18). DNA fragmentation following doxorubicin treatment is a strong stimulus to incur internal or mitochondrial apoptotic pathways via increasing the Bax/Bcl-2 ratio; in addition, it can assemble the bax- bax oligomers on mitochondrial membranes, resulting in increased mitochondrial outer membrane permeability (MOMP) and the release of cytochrome C, and activating the caspase-dependent intrinsic apoptotic pathways (19, 44, 45). Also, it was showed that doxorubicin remarkably increased neuronal cell death in the early and late days (22). In a human neuroblastoma model, doxorubicin prevented cell cycle progression in the G2/M and S phases (23).

The death of neurons seriously affects the normal activities of the brain, which is manifested by impaired cognitive functions such as learning and memory.

**Increased Oxidative Stress**

Doxorubicin causes neurotoxicity by facilitating ROS production and mitochondrial membrane depolarization in neurons (19, 22). Doxorubicin increases the MOMP and Bax/Bcl-2 ratio, leading to mitochondrial degeneration and neuronal dysfunction (19, 24). Previous studies have shown that both endogenic and ectogenic hydrogen peroxide can induce neural degeneration (25).

Except for being a site of ATP production, mitochondria are the main organelles which adjust calcium absorption and redox signaling under physiological conditions (46). It was found that doxorubicin damaged mitochondrial function in the hippocampus, resulting in elevated mitochondrial ROS levels and calcium disorder (26). In addition, glucose metabolism was declined in both the hippocampus and bilateral cortex after intra-thecal injection of doxorubicin (27). This damage may be generated by the opening of the mitochondrial permeability transition pore (mPTP), which is assembled between the mitochondrial membranes by three protein subunits including cyclophilin D (CyP-D), adenine nucleotide translocase (ANT), and VDAC (47). ROS initiates the activation of glycogen synthase kinase-3, which phosphorylates CyP-D into its active form. In addition, Calcium dysregulation contributes to mitochondrial membrane depolarization and ANT conformational changes. All these contribute to the mPTP formation, leading to abnormal solute divulgation and mitochondrial swelling (29, 47). Interestingly, injection of the antibodies against TNF-α or iNOS totally prevented the damage of mitochondrial oxidative reaction in mice, suggesting that doxorubicin reduces the mitochondrial function via inflammatory reaction and NO production (30).

Tangpong et al. showed that doxorubicin shifted p53 to the outer mitochondrial membrane, promoting its interaction with Bcl-xl (30), and this interplay caused the separation of Bax from Bcl-2 and Bcl-xl, led to Bax oligomerization and increased MOMP, resulting in the release of cytochrome C (30).

Mitochondria are the energy source of neurons, carrying out countless REDOX reactions all the time. Oxidative stress and neuron degeneration caused by abnormal mitochondria are one of the important causes of cognitive impairment (22).

**Effect on Autophagic Lysosomal System**

Doxorubicin can cause damage to the progenitor neuronal degradation pathways, impair progenitor neuronal lysosomes, promote the formation of pre-autophagic complexes, up-regulate autophagy, and affect the clearance of the autophagic marker p62 protein (31). Under electron microscopy, an accumulation of vacular structures, autophagosomes, mitochondria, and lipid droplets was observed in doxorubicin- exposed neurons (31).

Degradation disorders seriously affect the function of neurons, resulting in cognitive impairment after chemotherapy (31).

**Activation of Apoptosis**

It has been noted that doxorubicin-induced apoptosis is dependent on the exogenous pathway in primary cortical
neurons (death receptor-mediated apoptosis). Exogenous apoptotic pathway is a direct apoptotic mechanism mediated by doxorubicin. Doxorubicin increases Fas-Fas ligand (FasL) interactions, leading to the recruitment of Fas-associated protein with death domain (FADD) by connecting to the death domain, which initiates exogenous apoptotic pathways (32). Endogenous apoptotic pathways are activated by cellular stress, DNA damage, developmental signaling, and loss of survival factors. This pathway is regulated by Bcl-2 family proteins, and is related to the mechanism of mitochondrial oxidative stress, which has been described in detail above.

Abnormal apoptosis greatly reduces the number of neurons, thus leading to cognitive impairment (32).

**Damaged Neurogenesis**

The hippocampus is one of the structures closely associated with spatial processing and memory formation, and the integration of mature neurons in the circuit plays a key role in hippocampal function. The hippocampus is one of the structures closely associated with spatial processing and memory formation, and the integration of mature neurons in the circuit plays a key role in hippocampal function.

**TABLE 1 | The direct neurotoxicity of doxorubicin on chemo-brain.**

| Mechanism | Interpretation | Ref |
|-----------|----------------|-----|
| **Direct Neurotoxicity** | | |
| DNA Damage and Cell Cycle Disruption | DNA double-strand breaks; BRCA1, breast cancer type 1 susceptibility protein; ROS, reactive oxygen species; MOMP, mitochondrial outer membrane permeability; mPTP, mitochondrial permeability transition pore; PLD, phospholipase D; ChAT, choline acetyltransferase; AChE, acetylcholinesterase; 5-HT, serotonin; DA, dopamine; ERK, extracellular signal-regulated kinase; BDNF, brain-derived neurotrophic factor. | Manchon JF et al. (18) |
| Exogenous or mitochondrial apoptotic pathways; caspase-dependent intrinsic apoptotic pathways. | increased neuronal cell death in the early and late days. | Shokoohninia Y et al. (19) |
| | blocked cell cycle progression in the G2/M and S phases. | Lee YJ et al. (20) |
| | ROS production and mitochondrial membrane depolarization. | Shamas-Din A et al. (21) |
| | increased the Bax/Bcl-2 ratio and MOMP. | Ramalingayya GV et al. (22) |
| | both endogenic and ectogenic hydrogen peroxide can induce neural degeneration, elevated mitochondrial ROS levels and calcium disorder. | Pei Y et al. (23) |
| | glucose metabolism was decreased in both the bilateral cortex and hippocampus. | Shokoohninia Y et al. (19) |
| Mitochondrial dysfunction and Increased Oxidative Stress | | |
| | increased the Bax/Bcl-2 ratio and MOMP. | Shokoohninia Y et al. (19) |
| | either endogenic or ectogenic hydrogen peroxide can induce neural degeneration, elevated mitochondrial ROS levels and calcium disorder. | Lim I et al. (27) |
| | glucose metabolism was decreased in both bilateral cortex and hippocampus. | Javadov S et al. (28) |
| | the opening of the mPTP. | Wang CY et al. (29) |
| | interaction p53 with Bcl-xL. | Tangpong J et al. (30) |
| Direct Neurotoxicity | | |
| Effect on autophagic lysosomal system | | |
| Activation of apoptosis | Exogenous pathway in primary cortical neurons (death receptor-mediated apoptosis). | Walczak H et al. (32) |
| Damaged neurogenesis | reduced cell survival in the dentate gyrus and subgranular areas of rats. | Kitamura Y et al. (33) |
| Down-regulation of neurotransmitters | activation of astrocytes and subsequent release of inflammatory mediators. | Kohman RA et al. (34) |
| | the levels of PLD, ChAT activity, and choline-containing compounds in the hippocampal region were significantly declined. | Lim I et al. (27) |
| | doxorubicin-induced oxidative stress increased ROS-mediated AChE activity. | Keerey JTR et al. (35) |
| | reduced glutamate release. | Thomas TC et al. (36) |
| | TNF-α-induced activation of astrocytes triggers substantial glutamate release. | Habbas S et al. (37) |
| | reduced the levels of two monoamines: 5-HT and DA. | Kwatra M et al. (38) |
| Synaptic dysplasia | inhibits the growth of neurons, as evidenced by a decline in the number of neurons and a decrease in synapsin expression. | Manchon JF et al. (18) |
| Altered protein kinase signaling pathways | activate ERK and p38 MAPK. | El-Agamy SE et al. (39) |
| Epigenetic alterations | mRNA dysregulation is associated with the altered levels of BDNF. | Kovalchuk A et al. (40) |
neurogenesis (48). Animals treated with doxorubicin showed an obvious decrease in neurogenesis, as manifested by a distinct reduction in the number of neuro-specific nuclear antigen bromodeoxyuridine (BrdUrd)-labeled cells (49). Others also found that DOX in combination with cyclophosphamide reduced cell survival in the subgranular areas and dentate gyrus of rats (33).

A large number of studies have shown that activation of astrocytes and subsequent release of inflammatory mediators caused by doxorubicin render the nerve non-viable (50). TNF-α was reported to be anti-neurogenic, and can cause a decrease of the BrdUrd-labeled cells in the sub-granular zone following injection (51). Besides, mice deficient in TNF-α-receptor-1 (TNFR1) had an increased proliferation of BrdUrd-labeled cells in the sub-granular compartment, suggesting that TNFR1 mediates the anti-neurogenic effects of TNF-α (52). Neuro-inflammation not only affects the proliferation, differentiation, and survival of hippocampal cells, but also prevents the incorporation of new neurons into existing neural networks (53).

Down-Regulation of Neurotransmitters
Many animal researches have manifested that doxorubicin can cause dysregulation of neurotransmitter production and release in the brain. Acetylcholine (ACH) is a significant neurotransmitter in the cholinergic nervous system that supports brain functions through long-term potentiation (LTP) (54). During acetylcholine composition, phosphatidylcholine (PtdCho) is disintegrated by phospholipase D (PLD) and this releases choline, which is acetylated by choline acetyltransferase (ChAT) to form acetylcholine (55). In mice, the levels of PLD, ChAT activity, and choline-containing compounds in the hippocampal region were significantly declined after doxorubicin treatment, reflecting the exhaustion of ACH production (27)(35). Moreover, doxorubicin-induced oxidative stress increased ROS-mediated acetylcholinesterase (AChE) activity (36). Changes in the choline-containing substances are thought to be related to membrane turnover (synthesis and degradation of phospholipids), and have been attributed to myelin injury following chemotherapy (15).

Elevated TNF-α may decrease PLD activity, thereby inhibiting PtdCho synthesis (56). In addition, TNF-α is thought to be associated with decreases of phosphatidic acid levels, suggesting an interdependence between phospholipase and TNF-α expression (57).

Inhibition of PLD leads to decreased production of cytokines, including TNF-α (58, 59). Phosphatidic acid, an intermediate product of the PLD pathway, stimulates Ca2+ mobilization and displays growth factor-like activity, which helps reduce doxorubicin-induced mitochondrial dysfunction in the mouse brain (60). The enzymatic activity of PLD is critical for cell survival, and structural damage to PLD and reduced PLD activity may activate apoptotic pathways (37, 38, 61).

In addition to regulating acetylcholine metabolism, doxorubicin can alter glutamate levels in the synaptic gap. Doxorubicin reduced glutamate clearance, as showed by a decline in the rate of uptake of glutamate in the frontal cortex of mice (62). In this context, it was suggested that the decreased glutamate clearance is due to decreased expression of glial transport proteins or increased glutamate production from neurogliocyte, particularly in astrocytes (62). As mentioned earlier, TNF-α-induced activation of astrocytes triggers substantial glutamate release (63). When glutamate concentrations are high in the synapse, glutamate can diffuse to and combine with NMDA acceptors. Activation of extrasynaptic NMDA acceptors causes increased calcium-dependent excitability and suppression of BDNF composition, leading to loss of synaptic plasticity and increased neuronal apoptosis (39, 64). This may explain how doxorubicin decreased the expression of BDNF and its receptor tropomyosin receptor kinase B (TrkB) (26).

In addition, doxorubicin injection distinctly reduced the levels of two monoamines that are closely related to cognitive function: serotonin (5-HT) and dopamine (DA) (65). 5-HTergic
neurons play a significant role in regulating hippocampal synaptic plasticity through 5-HT1A receptor-mediated inhibitory control. Depletion of 5-HT negatively affects hippocampus-dependent declarative memory and performs poorly in a new object recognition task (66). During encoding, doxorubicin mediates the acquisition of long-lasting, long-term memory in the hippocampus by activating the D1/D5 receptor (67).

Changes in the levels of neurotransmitters lead to abnormalities in the transduction of nerve signals, leading to cognitive impairment.

### Synaptic Dysplasia
Abnormal synaptic plasticity in the brain is an important cause of cognitive impairment. Synaptic plasticity is associated with synaptic-associated proteins such as synapsin protein (SYP) and postsynaptic dense protein 95 (PSD95). In addition, the expression of brain-derived neurotrophic factor (BDNF)-synuclein (SYP)-microtubule-associated protein 2 (MAP2) pathway-related proteins in the hippocampus is also involved in the development of synaptic plasticity. Doxorubicin not only causes chromatin condensation and cell membrane fragmentation, but also inhibits the growth of neurons, as evidenced by a decline in the number of neurons and a decrease in synapsin expression, resulting in cognitive impairment (18, 22).

### Altered Protein Kinase Signaling Pathways
Doxorubicin can affect some key memory-related kinase systems. For instance, doxorubicin can activate p38 MAPK and extracellular signal-regulated kinase (ERK), two kinases that have opposite roles: while the former mediates synaptic inhibition, the latter promotes synaptic facilitation (40).

In hippocampal sensory neurons, doxorubicin can inhibit serotonin-induced long-term facilitation (LTF) and promote Phε-Met-Arg-Phe-NH2 (FMRFa)-mediated long-term depression (LTD), suggesting that doxorubicin may block learning-related changes in hippocampal excitability (40). However, p38-mediated inhibition of LTD was superior to ERK effects (40). The deviation of LTD was corrected by p38 inhibitors (68). These studies mean that long-term memory damage may be the result of doxorubicin action, partially due to the dominant activation of p38 MAPK (68). In addition, doxorubicin inhibited the phosphorylation of the downstream transcriptional repressor cAMP response element binding protein 2 (CREB2), which promoted LTD (40).

The ERK pathway is essential for neuronal survival (69) and is required for the synthesis of Arc, a protein that plays a crucial part in long-term memory formation, neuronal activity and synaptic plasticity (41). A recent study found an increase in Arc staining after doxorubicin treatment, suggesting that doxorubicin induces neuronal activity. On the contrary, inhibition of neuronal activity with n -methyl-d-aspartate (NMDA) receptor antagonists or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists partly eliminated the induction of DNA DSBs by doxorubicin, suggesting that doxorubicin-induced neurotoxicity is dependent on neuronal activity (18).

### Epigenetic Alterations
It has been reported that chemotherapy can trigger epigenetic reprogramming, another important mechanism that may contribute to persistent cognitive impairment (70). Homozygous mice exposed to chemotherapeutic agents show more pronounced disruptions in post-transcriptional regulation of gene expression, mainly miRNA changes in the prefrontal cortices. miRNA dysregulation is associated with the altered levels of brain-derived neurotrophic factor (BDNF) that plays a key role in cognition and memory (71).

### INDIRECT NEUROTOXICITY
Doxorubicin itself has a limited capacity to penetrate the blood-brain barrier; however, in the periphery, this agent can induce the production of a number of inflammatory factors and neurotransmitters that can pass through the BBB, thus affecting neurogenesis and survival, suggesting indirect neurotoxicity. The possible indirect mechanisms of doxorubicin induced chemo-brain are illustrated in Table 2 and Figure 1.

### Induction of Oxidative Stress
Peripheral inflammation and oxidative stress are believed to be responsible, at least in part, for doxorubicin-induced chemo-brain pathogenesis (30, 35, 84). Doxorubicin is a quinone-containing compound, a structure that is readily reduced by a single electron, and can be converted to semiquinone radicals by NADPH cytochrome P450 reductase (85), NADH dehydrogenase (mitochondrial complex I) (86), and cytoplasmic xanthine oxidase (87). The semiquinone form of doxorubicin can react with oxygen molecules and return to the natural quinone form, while forming a superoxide anion radical (O2−). This process is repeated following doxorubicin injection and is known as the redox cycle (72). O2− is a secondary product of ROS, including hydrogen peroxide (H2O2) and hydroxyl radicals (•OH), which can cause peripheral oxidative stress (73). Excess ROS production leads to the oxidative modification of biochemical molecules such as proteins, nucleic acids, and lipids (74). In clinical researches, doxorubicin-mediated increases of oxidative stress were indicated by increased protein oxidation and lipid peroxidation as well as decreased levels of enzymatic and nonenzymatic antioxidants (35, 84).

ROS can activate nuclear factor-κB (NF-κB), a redox-sensitive transcription factor, through a classical IκB kinase (IKK)-dependent pathway (88, 89). NF-κB activation enhances the expression of several pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α) (83), interleukin-1β (IL-1β), and interleukin-6 (IL-6) (90). It has been demonstrated that doxorubicin injection into mice caused an increase in plasma TNF-α levels 1 hour after the treatment (75). Similarly, serum cultures of isolated macrophages from the doxorubicin-treated mice show elevated levels of TNF-α (91). This suggests an interaction between oxidative stress and inflammatory factors.

Neuronal degeneration caused by oxidative stress is one of the important causes of cognitive impairment (91).
Inflammation

TNF-α can affect the volume of the hippocampus (65) and inhibit the long-term enhancing effects of hippocampal CA1 and the dentate gyrus (92). Circulating TNF-α is able to migrate into the brain via endothelial cells expressing TNF-α receptors 1 and 2 (TNFR1 and TNFR2) in the BBB (76, 77). Once in the brain and upon binding to receptors on glial cells, TNF-α can augment the inflammatory signals by activating astrocytes and microglia, which lead to the local production of TNF-α in the brain (78, 79). Binding of TNF-α to TNFR recruits intracellular proteins and transduces inflammatory signaling, leading to NF-κB translocating to the nucleus.

In addition to inflammatory cytokines, activation of microglia and astrocytes via TNFR1 can enhance the expression and activity of NOX, particularly NOX2, leading to an increase in ROS production. Moreover, expression and activity of NADPH oxidases (NOX), particularly NOX2, leading to an increase in ROS production (94). Additionally, circulating TNF-α can affect the volume of the hippocampus (80, 91, 93). It has been demonstrated that high concentrations of NOX2 translocates to the nucleus.

Nitrification Stress

Several in vivo studies have shown that doxorubicin can induce iNOS expression and elevate levels of nitric oxide (NO•) in the body (80, 91, 93). It has been demonstrated that high concentrations of NO• can react with O2•− to form peroxynitrite (ONOO−), one of the most detrimental oxidants (81). In the mice treated with doxorubicin, both NO• and ONOO− cause nitration by adding a 3-nitrotyrosine (3-NT) to the protein (91) (97). Studies have shown that an antioxidant enzyme, manganese superoxide dismutase (MnSOD), was nitrated in the mitochondria in the animals subjected to doxorubicin treatment, and the nitrated MnSOD resulted in impaired mitochondrial respiratory activity, which in turn synergized with O2•− production (30, 82).

Inflammatory processes and oxidative stress may exacerbate doxorubicin-induced neurotoxicity, and ultimately lead to neuronal apoptosis in the neurogenic regions of the brain.

### TABLE 2 | The indirect neurotoxicity of doxorubicin on chemo-brain.

| Mechanism          | Interpretation                                                                 | Ref                  |
|--------------------|--------------------------------------------------------------------------------|----------------------|
| Indirect Neurotoxicity | Induction of oxidative Stress | Excess ROS production leads to the oxidative modification of biochemical molecules such as proteins, lipids, and nucleic acids. ROS can activate NF-κB. |
|                    | Inflammation                   | TNF-α can affect the volume of the hippocampus. |
|                    |                                  | TNF-α can inhibit the long-term enhancing effects of hippocampal CA1 and the dentate gyrus. |
|                    |                                  | TNF-α can augment the inflammatory signals by activating astrocytes and microglia, which lead to the local production of TNF-α in the brain. |
|                    |                                  | Binding of TNF-α to TNFR recruits intracellular proteins and transduces inflammatory signaling, leading to NF-κB translocating to the nucleus. |
|                   | Nitrification Stress            | the nitrated MnSOD resulted in impaired mitochondrial respiratory activity, which in turn synergized with O2•− production. |
|                   | Apolipoprotein A-I              | ApoA-1 exerts anti-inflammatory effects by blocking contact between activated T lymphocytes and monocytes and inhibiting the production of TNF-α. |
|                   |                                  | ApoA-1 is sensitive to the doxorubicin-induced oxidative damage, leading to dyslipidemia and increased circulating TNF-α. |

**NF-κB, nuclear factor-κB; TNFR, TNF-α receptor; TNFR1, TNF-α receptor 1; NOX, NADPH oxidases; MnSOD: manganese superoxide dismutase; ApoA-1, Apolipoprotein A-I.**
CONCLUSIONS AND PROSPECT

It has been confirmed by a number of clinical as well as preclinical investigations that chemotherapy may cause cognitive impairment, and the mechanisms involved in the chemo-brain problem include DNA damage, oxidative stress, inflammatory responses, dysregulation of apoptosis and autophagy, altered neurotransmitter levels, aberration of some kinase, mitochondrial dysfunction, glial cell interactions, inhibition of neurogenesis, and epigenetic factors. Noteworthy, all of these mechanisms are inter-related and collectively involved in the development of the chemo-brain. Although there is no specific treatment for chemotherapy-induced cognitive impairment, it has been reported that rehabilitation behavioral training, such as cognitive behavioral therapy (CBT), neuropsychological/cognitive training intervention, physical activity, might improve the quality of life of the patients who suffer from chemo-brain. In addition, doxorubicin has limited ability to penetrate through the BBB and key factors in the induction of chemo-brain are oxidative stress and peripheral TNF-α products, antioxidant or anti-inflammatory therapy often can significantly improves chemo-brain. In fact, several pharmacological agents have shown promising benefits in blocking neurotoxic pathways through their antioxidant or anti-inflammatory action, such as 2-mercaptopoethane sulfonate sodium (MESNA) (100), donepezil (27), astaxanthin (AST) (36); however, their impact on the antitumor efficacy of chemotherapy regimens remains to be evaluated.

Chemotherapy is one of the most important modalities in the comprehensive treatment of breast cancer. In order to improve the therapeutic effect, chemotherapy regimens combining two or more drugs or sequential chemotherapy are often used in clinical practice. This review focuses on the mechanism of action of doxorubicin in causing cognitive impairment, yet, there are numerous studies showing that paclitaxel, cyclophosphamide, and platinum drugs are also associated with chemotherapy brain. We speculate that the cognitive deficits caused by these chemotherapeutic drugs also have multiple cross-linked mechanisms, such as pterostilbene causes neuronal abnormalities, apoptosis, neuroinflammation, and endoplasmic reticulum stress; cyclophosphamide induces dendritic abnormalities, oxidative damage, and DNA methylation in hippocampal granule cells; and platinum drugs affect brain glucose metabolism and cause mitochondrial damage. When different drugs are used in combination or sequentially, the mechanisms leading to chemotherapy of the brain become more complex. Therefore, more animal experiments and clinical studies are needed to elucidate the network of these mechanisms related to chemo-brain, to provide a theoretical basis for the treatment and prevention of cognitive disorders caused by different chemotherapy regimens, and to hopefully achieve evidence-based, precision medicine for chemotherapy-related cognitive disorders in the near future.

During our research, we found that cognitive function is highly susceptible to subjective factors, and that stress and negative emotions affect the brain by disrupting the body’s hormonal homeostasis. In addition, cancer, general anesthesia, and surgery can increase cytokine levels and cause cognitive impairment. Therefore, in future research, we should pay special attention to the selection of subjects and the design of experimental protocols. Currently, there is no unified standard for the diagnosis of chemotherapy-related cognitive impairment at home and abroad. Examination methods mainly include neuropsychological testing and imaging examinations. The Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) is a scale developed by Wagner et al. for the evaluation of subjective cognitive impairment in cancer patients, which has been proved to have good reliability and validity for breast cancer patients in China. Montreal Cognitive Assessment (MoCA) is an assessment tool for rapid screening of objective cognitive dysfunction, which is suitable for clinical application due to its high sensitivity and short test time for mild cognitive impairment. However, these neuropsychological tests are highly susceptible to subjective factors such as stress and negative emotions, and need to refer to objective cognitive assessment methods such as MRI. In recent years, multimodal magnetic resonance imaging (MRI) such as arterial spin labeling (ASL), blood oxygen level dependent (BOLD) functional MRI (fMRI), and diffusion tensor imaging (DTI) have been widely used to evaluate chemotherapy-induced breast cancer. This set of techniques significantly improves our understanding of the neural mechanisms underlying chemotherapy-induced cognitive dysfunction from a holistic and local brain structure and function perspective.

AUTHOR CONTRIBUTIONS

JD reviewed the mechanisms of doxorubicin-induced cognitive impairment, and was a major contributor in writing the manuscript. AZ revised the manuscript. JL analyzed and interpreted the patient data regarding the chemotherapy. HJ helped perform the analysis with constructive discussions. XL, SW, BW, and YW helped perform the analysis with constructive discussions. All authors contributed to the article and approved the submitted version.

FUNDING

The research fund was provided by General Project of Natural Science Foundation of Shanxi Province (201901D111347).

ACKNOWLEDGMENTS

This study was supported by Shanxi Medical University. Writing and editing of the manuscript were assisted by Hongyan Jia.
REFERENCES

1. Zandberg N, de Rooy BH, Vos MC, Pijnenborg JMA, Boll D, Kruitwagen RFPAM, et al. Changes in Health-Related Quality of Life Among Gynecologic Cancer Survivors During the Two Years After Initial Treatment: A Longitudinal Analysis. Acta Oncol (2019) 58(5):790–800. doi: 10.1080/0284186X.2018.1560498

2. Xu Z, Luo F, Wang Y, Zou BS, Man Y, Liu JS, et al. Cognitive Impairments in Breast Cancer Survivors Treated With Chemotherapy: A Study Based on Event-Related Potentials. Cancer Chemother Pharmacol (2020) 85(1):67–7. doi: 10.1007/s00280-019-03994-0

3. Yamada TH, Denburg NL, Beglinger LJ, Schultz SK. Neuropsychological Outcomes of Older Breast Cancer Survivors: Cognitive Features Ten or More Years After Chemotherapy. J Neuropsychiatry Clin Neurosci (2010) 22(1):48–54. doi: 10.1176/jnp.2010.22.1.48

4. Wang L, Apple AC, Schroeder MP, Ryals AJ, Voss JL, Gitelman D, et al. Reduced Prefrontal Activation During Working and Long-Term Memory Tasks and Impaired Patient-Reported Cognition Among Cancer Survivors Postchemotherapy Compared With Healthy Controls. Cancer (2016) 122(2):258–68. doi: 10.1002/cncr.29737

5. Groves TR, Farris R, Anderson JE, Alexander TC, Kiffer F, Carter G, et al. S-Fluorouracil Chemotherapy Upregulates Cytokines and Alters Hippocampal Dendritic Complexity in Aged Mice. Behav Brain Res (2017) 316:215–24. doi: 10.1016/j.bbr.2016.08.039

6. Jiang ZG, Winocur G, Wojtowicz JM, Shevtsova O, Fuller S, Ghanbari HA. Chemotherapeutic Agent Paclitaxel (Taxol) Reduces Hippocampal Dendritic Complexity in Aged Mice. Front Aging Neurosci (2018) 10:272. doi: 10.3389/fnagi.2018.00272

7. Aotani E, Hamano T, Gemma A, Takeuchi M, Takebayashi T, Kobayashi K. Chemotherapeutic Drug Paclitaxel Increases Hippocampal Dendritic Complexity in Aged Mice. Front Aging Neurosci (2018) 10:272. doi: 10.3389/fnagi.2018.00272

8. Du K, Xia Q, Heng H, Feng F. Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Cancer. Oncotarget (2019) 10(13):e52134. doi: 10.7554/eLife.52134

9. Manchon JF, Dubaghian Y, Uzor NE, Kesler SR, Wefel JS, Tsvetkov AS. Levetiracetam Mitigates Doxorubicin-Induced DNA and Synaptic Damage in Neuroblastoma. Sci Rep (2016) 6:25705. doi: 10.1038/srep25705

10. Sarder I, de Rooy BH, Vos MC, Pijnenborg JMA, Boll D, Kruitwagen RFPAM, et al. Changes in Health-Related Quality of Life Among Gynecologic Cancer Survivors During the Two Years After Initial Treatment: A Longitudinal Analysis. Acta Oncol (2019) 58(5):790–800. doi: 10.1080/0284186X.2018.1560498

11. Chou YH, Lin YJ, Yeh HJ, Lee SY, Hung CH, Shih SH, et al. Cognitive Impairments in Breast Cancer Survivors During the Two Years After Initial Treatment: A Longitudinal Analysis. Acta Oncol (2019) 58(5):790–800. doi: 10.1080/0284186X.2018.1560498

12. Lee YJ, Lee C. Porcine Deltacoronavirus Induces Caspase-dependent Apoptosis Through Activation of the Cytochrome C-mediated Intrins ic Mitochondrial Pathway. Virus Res (2018) 253:112–23. doi: 10.1016/j.virusres.2018.06.008

13. Shams-Din A, Brahmbhatt H, Leber B, Andrews DW. BHS-Only Proteins: Orchestrators of Apoptosis. Biochim Biophys Acta (2011) 1813(4):508–20. doi: 10.1016/j.bbamcr.2010.11.024

14. Ramalingayya GV, Cherupu SP, Nayak PG, Kishore A, Shenoy R, Rao CM, et al. Rutin Protects Against Neuronal Damage In Vitro and Ameliorates Doxorubicin-Induced Memory Deficits In Vivo in Wistar Rats. Drug Des De vel Ther (2017) 11:1011–26. doi: 10.2147/DDDT.S103511

15. Pei Y, Liu Y, Xie C, Zhang X, You H. Detecting the Formation Kinetics of Doxorubicin-DNA Intersand Cross-Link At the Single-Molecule Level and Clinically Relevant Concentrations of Doxorubicin. Anal Chem (2020) 92(6):4504–11. doi: 10.1021/acs.analchem.9b05657

16. Peng W, Rao D, Zhang M, Shi Y, Wu J, Nie G, et al. Tenevilitin Prevents Doxorubicin-Induced Apoptosis and Apoptosis In H9C2 Cells. Arch Biochem Biophys (2020) 683:108238. doi: 10.1016/j.abb.2019.108238

17. Errea O, Moreno B, Gonzalez-Franquesa A, Garcia-Roves PM, Villoslada P. The Disruption of Mitochondral Axonal Transport is an Early Event in Neuroinflammation. J Neuroinflamm (2015) 12:152. doi: 10.1186/s12974-015-0375-8

18. Park HS, Kim CJ, Kwak HB, No MH, Heo JW, Kim TW. Physical Exercise Prevents Cognitive Impairment by Enhancing Hippocampal Neuroplasticity and Mitochondrial Function in Doxorubicin-Induced Chemobrain. Neuropharmacology (2018) 133:451–61. doi: 10.1016/j.neuropharm.2018.02.013

19. Lim J, Joung HY, Yu AR, Shin I, Kim JS. Pet Evidence of the Effect of Donepezil on Cognitive Performance in an Animal Model of Chemobrain. BioMed Res Int (2016) 2016:6945415. doi: 10.1155/2016/6945415

20. Javadov S, Kuznetsov A. Mitochondrial Permeability Transition And Cell Death: the Role of Cyclophilin d. Front Physiol (2013) 4:76. doi: 10.3389/fphys.2013.00076

21. Wang CY, Yang TT, Chen CL, Lin CF. Reactive Oxygen Species-Regulated Glycogen Synthase Kinase-3β Activation Contributes to All-Trans Retinoic Acid-Induced Apoptosis in Granulocyte-Differentiated HL60 Cells. Biochem Pharmacol (2014) 88(1):86–94. doi: 10.1016/j.bcp.2013.12.021

22. Tangpong J, Cole MP, Yarn, AT, Estrada S, Vore M, St Clair W, et al. Doxorubicin-Mediated Nitration of Manganese Superoxide Dismutase in the Central Nervous System: Insight Into the Mechanism of Chemobrain. J Neurochem (2007) 100(1):191–201. doi: 10.1111/j.1471-4156.2006.04179.x

23. Moruno-Manchen JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, et al. TFEB Ameliorates the Impairment of the Autophagy-Lysosome Pathway in Neurons Induced by Doxorubicin. Aging (Albany NY) (2016) 8(12):3507–19. doi: 10.18632/aging.101144

24. Walczak H. Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation. Cold Spring Harb Perspect Biol (2013) 5(5):a008698. doi: 10.1101/cshperspect.a008698

25. Kitamura Y, Kanemoto E, Sugimoto M, Machida A, Nakamura Y, Naito N, et al. Influence of Nicotine on Doxorubicin and Cyclophosphamide Combination Treatment-Induced Spatial Cognitive Impairment and Anxiety-Like Behavior in Rats. Naunyn Schmiedebergs Arch Pharmacol (2017) 390(4):369–78. doi: 10.1007/s00210-016-1338-z

26. Kohnen RA, Rhodes JS. Neurogenesis, Inflammation and Behavior. Brain Behav Immun (2013) 27(1):22–32. doi: 10.1016/j.bbi.2012.12.009

27. Keeney JTR, Ren X, Warner G, Noel T, Powell DK, Brehlford JM, et al. Doxorubicin-Induced Elevated Oxidative Stress and Neurochemical Alterations in Brain and Cognitive Decline: Protection by MESNA and Insights Into Mechanisms of Chemobrain-Induced Cognitive Impairment ("Chemobrain"). Oncotarget (2018) 9(54):30324–39. doi: 10.18632/oncotarget.25718

28. El-Agamy SE, Abdel-Aziz AK, Wahdan S, Esmat A, Azab SS. Astaxanthin Ameliorates Doxorubicin-Induced Cognitive Impairment (Chemobrain) in...
Experimental Rat Model: Impact on Oxidative, Inflammatory, and Apoptotic Mechanisms. Mol Neurobiol (2018) 57(7):5727–40. doi: 10.1007/s12055-017-1024-4

37. Wu D, Zhang W, Chen Y, Hu H, Wang M. Platycodin D Inhibits Proliferation, Migration and Induces Chemosensitivity Through Inactivation of the NF-κB and JAK2/STAT3 Pathways in Multiple Myeloma Cells. Clin Exp Pharmacol Physiol (2019) 46(12):194–200. doi: 10.1111/1440-1681.13145

38. Tanguy E, Tran Nguyen AP, Kassas N, Bader MF, Grant NJ, Vitale N. Regulation of Phospholipase D by Arf6 During FcγR-Mediated Phagocytosis. J Immunol (2019) 202(10):2971–81. doi: 10.4049/jimmunol.1801019

39. Haroon E, Miller AH, Sanacora G. Inflammation-Induced Caspase-Dependent Inhibitors on Acute Pancreatitis: In Vitro and In Vivo Characterization. Drug Des Devel Ther (2020) 14:7465–74. doi: 10.2147/DDDT.S270443

40. Friday SC, Fox DA. Phospholipase D Enzymes Facilitate IL-17- and TNF-α Mediated Phagocytosis. Immunol Lett (2016) 174–9. doi: 10.1016/j.iml.2016.04.001

41. Urbahn MA, Kaup SC, Reuswig FW, Krüger I, Spelleken M, Jurik K, et al. Phospholipase D1 Regulation of TNF-α-Dependent Proteins Against Responses to LPS. Sci Rep (2018) 8(1):10006. doi: 10.1186/s13898-018-28331-y

42. da Silva Rosa SC, Martens MD, Field JT, Nguyen L, Kerenyi SM, Hai Y, et al. BNI313/Nix-Induced Mitochondrial Fission, Mitophagy, and Impaired Myocyte Glucose Uptake Are Braked by PKA/PKA Phosphorylation. Autophagy (2020) 12:1–16. doi: 10.1080/15548627.2020.1821548

43. Cordaro M, Impellizzeri D, Siracusa R, Gugliandolo E, Fusco R, Inverferra A, et al. Effects of a Co-Micronized CompositeContaining Palmitoylethanolamide and Polydatin in an Experimental Model of Benign Prostatic Hyperplasia: Toxiplos. Appl Pharm (2017) 329:231–40. doi: 10.1007/s11064-016-1949-2

44. Walker KR, Tesco G. Molecular Mechanisms of Cognitive Dysfunction Following Traumatic Brain Injury. Front Aging Neurosci (2013) 5:29. doi: 10.3389/fnagi.2013.00029

45. Kovalchuk A, Ilnytskyy Y, Rodriguez-Juarez R, Katz A, Sidransky D, Kolb B, et al. Gliosis and JAK2/STAT3 Pathways in Multiple Sclerosis-Mediated Phagocytosis. Neuroinflammation (2013) 23: doi: 10.18632/oncotarget.19835

46. Bethus I, Tse D, Morris RG. Dopamine and Memory: Modulation of the Persistence of Memory and Hippocampal Synaptic Plasticity. Neuropsychopharmacology (2015) 42(5):152–23. doi: 10.1002/npp.2016.134

47. Befuss I, Tse D, Morris RG. Dopamine and Memory: Modulation of the Persistence of Memory for Novel Hippocampal NMDA Receptor-Dependent Paired Associates. J Neurosci (2010) 30(5):1610–8. doi: 10.1523/JNEUROSCI.2721-09.2010

48. Liu RY, Zhang Y, Coughlin BL, Cleary LJ, Byrne JH. Doxorubicin Attenuates Serotonin-Induced Long-Term Synaptic Facilitation by Phyosphorylation of p38 Mitogen-Activated Protein Kinase. J Neurosci (2015) 35(40):12829–300. doi: 10.1523/JNEUROSCI.0538-14.2014

49. Liu S, Liu C, Xiong L, Xie J, Huang C, Pi R, et al. Icaritin Alleviates Glutamate-Induced Neuronal Damage by Inactivating GluN2b-Containing NMDARs Through the ERK/DAPK1 Pathway. Front Neurosci (2021) 15:525615. doi: 10.3389/fnins.2021.525615

50. Wang XM, Walilt B, Saligan L, Tiwari AF, Cheung CW, Zhang ZJ. Chemobrain: A Critical Review and Causal Hypothesis of Link Between Cytokines and Epigenetic Reprogramming Associated With Chemotherapy. Cytokine (2015) 72(1):86–90. doi: 10.1016/j.cytokine.2014.12.006

51. Kovalchuk A, Ilnytskyy Y, Rodriguez-Juarez R, Katz A, Sidransky D, Kolb B, et al. Growth of Malignant Extracranial Tumors Alters microRNAome in the Prefrontal Cortex of TumorGraft Mice. Oncotarget (2017) 8(51):88276–93. doi: 10.18632/oncotarget.19835

52. Zhu H, Sarkar S, Scott L, Danelisen J, Trush MA, Jia Z, et al. Doxorubicin Redox Biology: Redox Cycling, Toxiposism and Inhibition, and Oxidative Stress. React Oxid Spec (Apex) (2016) 13(3):189–98. doi: 10.20455/roso.2016.835

53. Malik A, Sultana M, Qazi A, Qazi MH, Parveen G, Waqar S, et al. Role of Natural Radiosensitizers and Cancer Cell Radiosensitivity: An Update. Anil Cell Pathol (Amst) (2020) 16(6):164695. doi: 10.1155/2020/64695

54. Birben E, Sahiner UM, Sakescen C, Erzurum S, Kalyaci O. Oxidative Stress and Antioxidant Defense. Epub (2012) 5(1):9–19. doi: 10.1097/WOB.0b013e3182439613
75. Tangpong J, Cole MP, Sultana R, Gosh G, Estus S, Vore M, et al. Doxorubicin-Induced, TNF-α/β-Mediated Central Nervous System Toxicity. Neurobiol Aging (2020) 80(1):127–39. doi: 10.1016/j.neurobiolaging.2019.09.013

76. Wang LW, Chang YC, Chen SJ, Tseng CH, Tu YF, Liao NS, et al. Tnfα-JNK Signaling is the Shared Pathway of Neuroinflammation and Neurovascular Damage After LPS-sensitized Hypoxic-Ischemic Injury in the Immature Brain. J Neuroinflamm (2014) 11:215. doi: 10.1186/s12974-014-0215-2

77. Molino Y, Jabès F, Bonnet A, Gaudin N, Bernard A, Benech P, et al. Gene Expression Comparison Reveals Distinct Basal Expression of HOX Members and Differential TNF-induced Response Between Brain- and Spinal Cord-Derived Microvascular Endothelial Cells. J Neuroinflamm (2016) 13(1):290. doi: 10.1186/s12974-016-0749-6

78. Guidotti G, Scarlata C, Brambilla L, Rossi D. Tumor Necrosis Factor Alpha in Amyotrophic Lateral Sclerosis: Friend or Foie? Cells (2021) 10(3):518. doi: 10.3390/cells10030518

79. Zhou H, Zhou M, Hu Y, Limpanon Y, Ma Y, Huang P, et al. TNF-α Triggers Rip1/Fadd/Caspase-8-Mediated Apoptosis of Astrocytes and RIP3/MKL1-Mediated Necroptosis of Neurons Induced by Angiotensinogen Cantonensis Infection. Cell Mol Neurobiol (2021) 12(10):1–3. doi: 10.1007/s10571-021-01063-w

80. Mohamed RH, Karam RA, Amer MG. Epicatechin Attenuates Doxorubicin-Induced Brain Toxicity: Critical Role of TNF-α, iNOS and NF-kB. Brain Res Bull (2011) 86(1-2):22–8. doi: 10.1016/j.brainresbull.2011.07.001

81. Adesina DO, Salu SG, Adesina JO. Oxide in Seawater: The Peroxynitrite Sink and its Implications for Daytime Air Quality. Sci Total Environ (2021) 781:146683. doi: 10.1016/j.scitotenv.2021.146683

82. Holley AK, Bakhavatchala V, Velez-Roman JM, St Clair DK. Manganese Superoxide Dismutase: Guardian of the powerhouse. Int J Mol Sci (2011) 12(10):7114–62. doi: 10.3390/ijms12107114

83. Liu T, Zhang L, Joo D, Sun SC. NF-kB Signaling in Inflammation. Signal Transduct Target Ther (2017) 2(1):203. doi: 10.1038/sigtrans.2017.23

84. Alisei CD, Miriyala S, Noel T, Sultana R, Jungsuwadee P, Taylor TJ, et al. 2-Mercaptoethane Sulfonate Prevents Doxorubicin-Induced Plasma Protein Oxidation and TNF-α Release: Implications for the Reactive Oxygen Species-Mediated Mechanisms of Chemobrain. Free Radic Biol Med (2011) 50(11):1630–8. doi: 10.1016/j.freeradbiomed.2011.03.009

85. Pan SS, Pedersen L, Bachur NR. Comparative Flavoprotein Catalysis of Anthracycline Antibiotic. Reductive Cleavage and Oxygen Consumption. Mol Pharmacol (1981) 19(1):184–6.

86. Wong TW, Yu HY, Kong SK, Fung KP, Kwok TT. The Decrease of Mitochondrial NADH Dehydrogenase and Drug Induced Apoptosis in Doxorubicin Resistant A431 Cells. Life Sci (2000) 67(9):1111–8. doi: 10.1016/S0024-3205(00)00699-8

87. Yee SB, Pritsos CA. Comparison of Oxygen Radical Generation From the Reductive Activation of Doxorubicin, Streptonigrin, and Menadione by Xanthine Oxidase and Xanthine Dehydrogenase. Arch Biochem Biophys (1997) 347(2):235–41. doi: 10.1006/abbi.1997.0340

88. Herb M, Gluschko A, Wiegmann K, Farid A, Wolf A, Utermöhlen O, et al. Mitochondrial Reactive Oxygen Species Enable Proinflammatory Signaling Through Disulfi de Linkage of NEMO. Sci Signal (2019) 12(568):ear5926. doi: 10.1126/scisignal.ear5926

89. Yan S, Zhang X, Zheng H, Hu D, Zhang Y, Guan Q, et al. Clematichineoxirone Inhibits VCAM-1 and ICAM-1 Expression in TNF-α-Treated Endothelial Cells Via NADPH Oxidase-Dependent 1sβ Kinase/NF-κB Pathway. Free Radic Biol Med (2015) 78:190–201. doi: 10.1016/j.freeradbiomed.2014.11.004

90. Ishikawa T, Abe K, Takana-Ishikawa M, Yoshida K, Watanabe T, Imakire S, et al. Chronic Inhibition of Toll-Like Receptor 9 Ameliorates Pulmonary Hypersensitivity in Rats. J Am Heart Assoc (2021) 10(7):e019247. doi: 10.1161/JAHA.120.019247

91. Tangpong J, Miriyala S, Noel T, Sinthupibulyakit C, Jungsuwadee P, St Clair DK. Doxorubicin-Induced Central Nervous System Toxicity and Protection by Xanthone Derivative of Garcinia Mangostana. Neuroscience (2011) 175:292–9. doi: 10.1016/j.neuroscience.2010.11.007

92. Motaghinejad M, Motevallian M, Abdollahi M, Heidari M, Madjd Z. Topiramate Confers Neuroprotection Against Methylene-Induced Neuregeneration in Dentate Gyrus and CA1 Regions of Hippocampus Via CREB/BDNF Pathway in Rats. Neurotox Res (2017) 31(3):573–99. doi: 10.1007/s12640-016-9695-y

93. Wu YQ, Dang RL, Tang MM, Cai HL, Li HD, Liao DH, et al. Long Chain Omega-3 Polysaturated Fatty Acid Supplementation Alleviates Doxorubicin-Induced Depressive-Like Behaviors and Neurotoxicity in Rats: Involvement of Oxidative Stress and Neuroinflammation. Nutrients (2016) 8(4):243. doi: 10.3390/nu8040243

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.